AOD-9604: the fat-burning peptide, fact-checked

What is AOD-9604?

AOD-9604 stands for Anti-Obesity Drug 9604 — a synthetic peptide derived from human growth hormone (hGH). Specifically, it is the 16-amino-acid C-terminal fragment of the hGH molecule, residues 176–191, sometimes written as hGH fragment 176–191.

It is not growth hormone, and it is not a GH secretagogue. It's a specific fragment, selected because early research suggested it retained fat-burning activity without GH's broader effects.

The history

AOD-9604 was developed by Metabolic Pharmaceuticals, an Australian company, with the underlying research originating at Monash University. It was developed and patented in the late 1990s as part of a program to create an obesity treatment based on GH fragments.

The idea was elegant. Growth hormone has lipolytic (fat-burning) effects, but also unwanted ones — IGF-1 elevation, insulin resistance, fluid retention. A fragment that retained the fat-burning without the problems could be a cleaner candidate. Phase I and Phase II trials ran through the mid-2000s.

Then the program ran into trouble. Development was discontinued in 2007 after a larger Phase IIb trial failed to meet its endpoints. No Phase III trial followed. Despite this, AOD-9604 has persisted in the research-peptide world, often cited with claims that outrun the data.

How is AOD-9604 thought to work?

The proposed mechanisms come largely from early research, much of it in animals.

• Lipolytic activity — AOD-9604 is proposed to stimulate lipolysis, the breakdown of stored fat into free fatty acids. The suggested route: it binds receptors on adipose tissue and activates adenylyl cyclase, raising cAMP, which activates hormone-sensitive lipase (HSL) to break down triglycerides — the same basic pathway used by epinephrine and beta-3 agonists.
• Reduced lipogenesis — some early research suggested it may also reduce fat storage.
• No significant IGF-1 elevation — the key proposed difference from full GH. AOD-9604 does not appear to meaningfully raise IGF-1, which is tied to insulin resistance, fluid retention, and cancer-risk concerns. That finding, however, comes mostly from early animal studies; human data is limited.

What the research actually shows

Animal studies. Obese rodents treated with AOD-9604 showed reduced body fat and improved lipid profiles versus controls, apparently without the insulin resistance or fluid retention seen with full GH. Lipolytic activity was reported in mice, rats, and dogs — enough to justify moving into human trials.

Human clinical trials. Phase I tested safety in a small number of subjects, with no major safety signals reported. Phase II tested efficacy in obesity, and the results were underwhelming — and never published in a peer-reviewed journal, so what's known comes from conference abstracts and company statements. Per those reports: statistically significant weight loss versus placebo, but a modest magnitude of roughly 2–3 kg over 12 weeks, against a high placebo response. It was not compelling enough to advance, and no Phase III trial was ever conducted.

The evidence gap. AOD-9604 has never been studied in a large, randomized, placebo-controlled Phase III trial. What exists is animal data suggesting lipolytic activity, limited Phase I/II human data suggesting a modest effect, no published Phase III, and no long-term safety data. That places it in a fundamentally different category from GLP-1 peptides, which carry extensive published Phase III evidence (roughly 15–22% body-weight loss for semaglutide and tirzepatide).

AOD-9604 vs. GLP-1 peptides

The comparison isn't meant to dismiss AOD-9604 as a research compound. It's meant to establish that AOD-9604 sits at a fundamentally different stage of evidence development than the GLP-1 drugs.

Why does AOD-9604 still get attention?

A few reasons, none of them outcomes data. The GH-fragment hypothesis is theoretically elegant. There's a perception of safety — it's a fragment of a natural hormone, which is an assumption rather than a finding. Internet communities recommend it frequently, often citing early animal studies while ignoring the failed Phase II. And it remains available as a research peptide, independent of how the trials turned out.

Common claims about AOD-9604 — fact-checked

• "AOD-9604 is a fat-burning peptide with no side effects." Unproven. The side-effect profile was not well-characterized in the limited human trials.
• "AOD-9604 works as well as growth hormone for fat loss." False. Phase II showed modest weight loss at best.
• "AOD-9604 is FDA-approved." It was never approved as a drug. It did later receive self-affirmed GRAS ("generally recognized as safe") status around 2014 for use as a dietary-supplement/food ingredient — a separate pathway from drug approval, and not the same thing as being approved as a medicine.
• "AOD-9604 preserves muscle while burning fat." Speculative. Not demonstrated in peer-reviewed human research.

Sourcing notes

• Third-party CoA — required.
• Purity — 95%+, ideally 98%+.
• CAS number — 221231-10-3, useful for verifying identity against CoA data.
• Storage — refrigerated or frozen, protected from light.
• Quality — varies between suppliers; the research-grade market is not well-regulated.

The bottom line

AOD-9604 is a scientifically interesting peptide. The GH-fragment hypothesis is reasonable, the early animal data was encouraging, and the proposed mechanism is plausible. But it failed Phase II for obesity, the weight loss was modest, the data was never peer-reviewed, and no Phase III followed.

Comparing it to GLP-1 peptides isn't a fair fight: the GLP-1 drugs have extensive Phase III data showing roughly 15–22% body-weight loss, while AOD-9604 has Phase II data suggesting 2–3 kg over 12 weeks. For researchers, it remains a legitimate area of mechanistic study. For anyone else, the online excitement significantly outpaces the evidence.